Table 1.
Baseline characteristics of patients with fever and neutropenia (N = 337)
| Characteristics | Value (%) |
|---|---|
| Age (median, range) | 5.9 yrs (2.4 months–21.6 yrs) |
| Sex, males | 182 (54) |
| Race | |
| Caucasian | 252 (75) |
| African American | 50 (15) |
| Others | 34 (10) |
| Diagnosis | |
| Leukemia/Lymphoma/MDS* | 221 (66) |
| Solid Tumor | 116 (34) |
| Relapse (malignancy) | 60 (18) |
| Central Venous Line | 321 (95) |
| Steroids in the past 14 days | 118 (35) |
| On G-CSF* | 96 (28) |
| Antifungal therapy in the past 6 months | 26 (8) |
| Antibacterial prophylaxis other than TMP/SMX* | 30 (9) |
| Antifungal prophylaxis with Voriconazole | 59 (17) |
| Interval since last chemotherapy (median, range) | 5.0 days (0 days–1.4 yrs) |
| Duration of neutropenia preceding presentation (median, range) | 11.0 days (1 day – 4.9 months) |
*
VRE, vancomycin-resistant enterococcus; MRSA, methicillin-resistant Staphylococcus aureus;
URI, upper respiratory infection; ANC, absolute neutrophil count; Plts, platelets; TMP/SMX, trimethoprim/sulfamethoxazole; G-CSF, granulocyte-colony stimulating factor; MDS, myelodysplastic syndrome.